Moderna shares advanced more than 9 percent in premarket trading after the company said it had reached a global settlement that resolves all litigation with Arbutus Biopharma and Genevant Sciences involving its COVID-era vaccine technology.
The company characterized the agreement as one that "provides certainty going forward" for its infectious disease programs, specifically naming candidates such as mNEXSPIKE and mCOMBRIAX. Under the terms, Moderna will not owe future royalties tied to the settled claims.
Financially, Moderna disclosed it will make a payment of $950 million in the third quarter of 2026 and will record the charge in the first quarter. The company said it will continue to contest the District Court's Section 1498 ruling on the grounds that government-contractor immunity limits its liability, and has lodged an appeal.
Moderna also stated that it has not booked an accrual for a potential additional payment of up to $1.3 billion because a loss on that item "is not considered probable." The company added that if its appeal is ultimately successful at any stage, Arbutus and Genevant would be required to refund any additional payment with interest.
Chief Executive Officer Stéphane Bancel said resolving the dispute "removes uncertainty and allows us to turn our full focus to Moderna's exciting near-term future," while flagging expectations for revenue growth in 2026 and progress toward breakeven in 2028.
Market analysts reacted to the settlement. Barclays analyst Eliana Merle said the deal "lifts an overhang," observing that the combined total range of $1 billion to $2.25 billion was "much less than investors expected." Merle pointed to upcoming Phase 3 melanoma data as a key 2026 catalyst, noting that positive results could materially alter the stock's outlook.
On liquidity, Moderna now forecasts ending 2026 with $4.5 billion to $5 billion in cash. The company also has access to a $900 million credit facility, which it says could bring total projected liquidity to as much as $5.9 billion.
Separately, the article referenced tools that evaluate Arbutus Biopharma (ABUS) alongside other companies using AI-driven analysis and many financial metrics, noting the AI's role in generating stock ideas and comparing ABUS to other opportunities. The mention reflects the availability of analytical products that assess company fundamentals, momentum, and valuation.
Summary
A global settlement between Moderna, Arbutus Biopharma, and Genevant Sciences has removed ongoing litigation tied to COVID-era vaccine technology, prompted a premarket stock rally for Moderna, and established a $950 million payment schedule while leaving an appeal and the potential for an additional payment unresolved.